ArticleContemporary clinical trials communications2026
Protocol for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiation.
Article in Contemporary clinical trials communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06377696 (Neuro-Oncology Anywhere), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients With History of Cranial Radiation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive symptoms are among the most frequently reported issues in cancer patients treated with cranial radiation, yet they remain inadequately assessed in clinical practice and are suboptimally treated. Cranial radiation is an integral part of treatment for primary and metastatic brain tumors that contributes to progressive and irreversible cognitive decline with currently limited therapeutic options. Development of effective interventions that can prevent or delay this neurocognitive toxicity requires accurate assessment of symptom burden. However, formal neuropsychological testing is resource intensive and time consuming. Repeated in-person assessments are often not feasible for cancer patients who must travel great distances to specialized cancer centers. The Neuro-Oncology Anywhere (NOA) study is a fully decentralized clinical trial with an overarching goal to evaluate remote cognitive assessments while simultaneously evaluating benefits of health promotion through use of a wearable watch device and metformin in preventing radiation-related cognitive decline. The primary objective of this study is to determine the feasibility of completing serial remote cognitive, activity/sleep, and self-reported assessments among patients who have previously received cranial radiation. Key secondary objectives are to assess satisfaction of patients with remote monitoring, evaluate adherence to study drug, and compare neurocognitive function scores and the impact of receiving metformin and health promotion with a wearable device compared to wearable device alone. Determination of the remote platform's feasibility among patients with brain tumors will provide a strong scientific foundation for routinely integrating scalable remote cognitive assessment strategies into future clinical trials, enabling accelerated evaluation of potentially effective interventions unconstrained by geographic limitations. Trial registration id: NCT06377696.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.